PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections ...

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections ...

The imaging was better than societal recommendations at discriminating long-term risk of ventricular arrhythmias.

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients ...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 ...

In this FirefighterNation.com article, learn about the PPE challenges women firefighters face in the fire service.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug ...

Merck reports positive results from the first two phase 3 CORALreef trials of enlicitide decanoate to treat adults with hyperlipidemia: Rahway, New Jersey Tuesday, June 10, 2025, ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The physical toll of parenting and caregiving is resulting in a significant rise in orthopedic conditions among primary caregivers, according to specialists at Mercy Health in a news release.